Compare ESNT & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESNT | VANI |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 119.0M |
| IPO Year | 2013 | 2014 |
| Metric | ESNT | VANI |
|---|---|---|
| Price | $68.14 | $1.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $67.29 | $3.50 |
| AVG Volume (30 Days) | ★ 489.3K | 231.2K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 0.73 | N/A |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $1,260,935,000.00 | $4,000,000.00 |
| Revenue This Year | $1.12 | N/A |
| Revenue Next Year | $3.37 | N/A |
| P/E Ratio | $17.63 | ★ N/A |
| Revenue Growth | ★ 1.45 | N/A |
| 52 Week Low | $55.34 | $0.92 |
| 52 Week High | $70.37 | $1.92 |
| Indicator | ESNT | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 40.80 |
| Support Level | $67.89 | $1.26 |
| Resistance Level | $68.62 | $1.55 |
| Average True Range (ATR) | 1.06 | 0.08 |
| MACD | -0.22 | -0.02 |
| Stochastic Oscillator | 44.28 | 3.74 |
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.